Lixisenatida en pacientes con diabetes tipo 2 y obesidad: más allá del control glucémico

AIM: To evaluate tolerance to lixisenatide and its effects on weight and metabolic control in type 2 diabetes and obese patients. DESIGN: Prospective study. SETTING: Endocrinology clinics in Almeria, Granada and Malaga. PARTICIPANTS: Patients with type 2 diabetes and obesity. INTERVENTIONS: Response and tolerance to lixisenatide treatment. MAIN MEASUREMENTS: Clinical and analytical data of the subjects were evaluated at baseline and after treatment. RESULTS: The study included 104 patients (51% women) with type 2 diabetes and obesity (Almeria 18.3%; Granada 40.4%; Malaga 41.3%). The mean age was 58.4 ± 10.5 years, and the mean duration of diabetes was 11.2 ± 6.7 years. The patients were re-evaluated at 3.8 ± 1.6 months after treatment with lixisenatide. Significant improvements were found in weight (P < .001), body mass index (P < .001), waist circumference (P = .002), systolic blood pressure (P < .001), diastolic blood pressure (P = .001), fasting glucose (P < .001), HbA1c (P = .022), Total cholesterol (P < .001), LDL-cholesterol (P = .046), triglycerides (P = .020), hypertension drugs (P < .001), and lipids drugs (P < .001). No changes were observed in levels of amylase related to lixisenatide treatment, and 7.9% of patients did not tolerate it. CONCLUSIONS: Lixisenatide achieved significant improvements in anthropometric parameters, glycaemic control (fasting glucose and HbA1c), blood pressure and lipids. It was safe and well tolerated in most patients. In addition, there was a significant increase in the use of antihypertensive and lipid-lowering therapy.